TScan Therapeutics Inc., a clinical-stage biotechnology company, reported its financial results for the second quarter of 2025. The company achieved revenue of $3.1 million, a significant increase from the $0.5 million reported in the second quarter of 2024. This rise was primarily attributed to the timing of research activities under the company's collaboration agreement with Amgen. The net loss for the second quarter of 2025 was $37.0 million, compared to $31.7 million in the same period of the previous year. General and administrative expenses rose to $9.1 million from $7.8 million in the second quarter of 2024, driven by increased personnel expenses due to higher headcount. Research and development expenses also increased to $32.6 million from $26.9 million, largely due to higher costs in laboratory supplies and expansion of internal manufacturing capabilities. As of June 30, 2025, TScan Therapeutics held cash, cash equivalents, and marketable securities totaling $218.0 million, excluding $5.0 million of restricted cash. The company anticipates that these resources will support its operations into the first quarter of 2027. TScan Therapeutics plans to dose its first patients with multiplex TCR-T therapy in solid tumors in the third quarter of 2025 and aims to share initial safety and response data by the first quarter of 2026. Additionally, two-year relapse data from the ALLOHA™ Phase 1 heme trial is expected to be presented by the end of the year.